Related Experiment Video
Updated: May 10, 2025
12:23
In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses
Published on: September 7, 2022
1.6K
Aptamer-engaged nanotherapeutics against SARS-CoV-2
Jing Zhang1, Dan Wang2, Chiu Kwok3
1Life Science and Chemistry College, Hunan University of Technology, Zhuzhou, 412007, China.
Discover Nano
|April 27, 2025
Summary
Aptamers and nanotherapeutics offer promising COVID-19 treatments by neutralizing SARS-CoV-2. This review explores their therapeutic potential, challenges, and future in managing infectious diseases.
Area of Science:
- Molecular Biology
- Nanotechnology
- Infectious Disease Management
Background:
- The COVID-19 pandemic highlights the need for effective SARS-CoV-2 therapeutics.
- Aptamers and nanotherapeutics present a significant approach for viral neutralization and disease control.
Purpose of the Study:
- To provide a comprehensive review of aptamers and nanotherapeutics for COVID-19 treatment.
- To examine aptamer properties, therapeutic strategies, and integration with nanomedicine.
Main Methods:
- Review of aptamer selection, recognition mechanisms, and therapeutic applications.
- Exploration of aptamer-nanomedicine integration for COVID-19.
- Analysis of challenges including stability, delivery, and scalability.
Main Results:
- Aptamers demonstrate high affinity for SARS-CoV-2 targets, inhibiting viral entry and replication.
- Nucleic acid nanomedicine enhances aptamer therapeutic potential.
- Key challenges in stability, delivery, and manufacturing scalability were identified.
Conclusions:
- Aptamers and nanotherapeutics hold significant promise for COVID-19 treatment and future pandemic preparedness.
- Continued research is crucial to overcome challenges and advance clinical applications.
